Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) shares saw an uptick in trading volume on Thursday . 17,061,155 shares changed hands during mid-day trading, an increase of 2,751% from the previous session’s volume of 598,334 shares.The stock last traded at $2.33 and had previously closed at $1.75.
Separately, ValuEngine raised shares of Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
What are top analysts saying about Ampio Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ampio Pharmaceuticals and related companies.